Health

Leapstack has raised nearly 200 million RMB in Series C+ Funding, building a diversified technological value chain for health insurance

SHANGHAI, Jan. 18, 2024 /PRNewswire/ -- Leapstack, a prominent insurtech company, recently secured an impressive200 million RMB yuan in Series C+ Funding, led by Qiming Venture Partners. The funding round also saw active participation from Soochow Yihe Capital, and existing shareholder Legend Ca...

2024-01-18 22:34 1808

Leapstack has raised nearly 200 million RMB in Series C+ Funding, building a diversified technological value chain for health insurance

SHANGHAI, Jan. 18, 2024 /PRNewswire/ -- Leapstack, a prominent insurtech company, recently secured an impressive200 million RMB yuan in Series C+ Funding, led by Qiming Venture Partners. The funding round also saw active participation from Soochow Yihe Capital, and existing shareholder Legend Ca...

2024-01-18 22:18 1835

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

IRVINE, Calif., Jan. 18, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia (...

2024-01-18 16:00 2248

Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Indonesia

* Boehringer Ingelheim recognized as one of 17 Top Employers worldwide and for the sixth consecutive year inIndonesia * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development JAK...

2024-01-18 12:00 1360

Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Malaysia

* Boehringer Ingelheim recognized as one of 17 Top Employers worldwide and for the sixth consecutive year inMalaysia * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development KUALA ...

2024-01-18 12:00 1325

Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Thailand

* Boehringer Ingelheim recognized as one of 17 Top Employers worldwide and for the sixth consecutive year inThailand * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development BANGKO...

2024-01-18 12:00 1312

Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Asia Pacific

* Boehringer Ingelheim is recognized as one of 17 Top Employers worldwide and for the fifth consecutive year inAsia Pacific * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development...

2024-01-18 12:00 1509

Asian Smart Medical Online Exhibition 2024 Grand Opening

TAIPEI, Jan. 18, 2024 /PRNewswire/ -- Asian Smart Medical Online Exhibition (Medical Asia 2024) is a virtual and physical integration targeting Asian suppliers, importers, and exporters. It will be exhibited fromJanuary 17, 2024, toJune 30, 2024, and will be an excellent opportunity for exhibitor...

2024-01-18 11:08 1615

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in theUSA * The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in theUSA MELBOURNE, Australia ,Jan. ...

2024-01-18 10:31 1180

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024

* Octapharma will present new clinical and scientific findings for wilate® and Nuwiq® * New findings in von Willebrand disease (VWD) and haemophilia A, will be presented by leading experts in a Satellite Symposium, as well as an oral and six poster presentations * Presentations will include...

2024-01-18 02:20 1629

Seal Storage Technology Bolsters Compliance with HIPAA-Compliant Blockchain-Based Data Storage

TORONTO, Jan. 17, 2024 /PRNewswire/ -- - Seal Storage Technology, a leading provider of blockchain-powered cloud storage, is now able to enter Business Associate Agreements (BAAs) to handle protected health information (PHI) with its completion of HIPAA certification. Seal's compliance with HIPAA...

2024-01-17 23:45 1349

Seno Medical Earns Frost & Sullivan's 2023 United States Enabling Technology Leadership Award for Delivering a More Efficient Breast Cancer Diagnosis with Its Cutting-edge Technology

Seno Medical offers highly differentiated opto-acoustic/ultrasound (OA/US) exam to diagnose breast cancer and significantly reduce unnecessary breast biopsies. SAN ANTONIO, Jan. 17, 2024 /PRNewswire/ -- Frost & Sullivan recently recognizedSeno Medical with the 2023 US Enabling Technology Leadersh...

2024-01-17 23:00 1402

Lunit INSIGHT CXR Excels in Lung Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology

- Lunit's AI-powered chest X-ray analysis solution shows highest AUC of 0.93 in a recent multi-center, multi-use case, multi-vendor lung nodule detection study SEOUL, South Korea, Jan. 17, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostic...

2024-01-17 22:15 1395

Shaping International Economics and Ethical Dialogues Through the Leadership of Cheah Chyuan Yong

KUALA LUMPUR, Malaysia, Jan. 17, 2024 /PRNewswire/ -- Under the visionary leadership ofCheah Chyuan Yong, the International Strategy Institute (ISI) proudly declares the successful conclusion of two groundbreaking global conferences: the 12th World Chinese Economic Forum (WCEF) and the World Ant...

2024-01-17 21:41 1731

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansionshowed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - - Preliminary survival analysis of ADG126 10 mg/kg do...

2024-01-17 20:00 2461

Envision Energy Announces Collaboration with Five Global Healthcare Leaders to Unlock Renewable Energy in Davos

Envision Energy signed a three-year renewable energy supply agreement with AstraZeneca, Lonza, Novartis, Novo Nordisk and Roche, to offer around 200 gigawatt-hours (GWh) of green power annually from 2024, resulting in annual carbon dioxide equivalent savings of approximately 120,000 tons.  ...

2024-01-17 14:50 1636

Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

SUZHOU, China, and ROCKVILLE, Md., Jan. 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that olverembatinib (R&D Code: HQP1351) has been ...

2024-01-17 12:10 3788

WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, highly flexible engineering platform that greatly enhances the deve...

2024-01-17 08:30 3818

SeptiCyte RAPID® By Immunexpress Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA)

The Cost of Sepsis in Australia report (2021) estimated that there are >90,000 sepsis cases inAustralia each year and estimated direct and indirect costs of $700 million and $4 billion respectively SEATTLE and BRISBANE, Australia, Jan. 17, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular...

2024-01-17 06:00 1643

Health In Tech Takes Center Stage at Greek House Annual Meeting at the World Economic Forum 2024 in Davos, Showcasing Innovation and Leadership

STUART, Fla., Jan. 16, 2024 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and re-imagines self-funded health plans, is set to make waves at the Greek House Annual Meeting at the Greek House Annual Meeting at the World Economic Forum 2024...

2024-01-17 00:32 1460
1 ... 49505152535455 ... 822